At close: December 13 at 9:35:20 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
13,466.7600
7,812.8950
3,475.5340
16,038.1070
15,974.9440
Operating Income
-13,466.7600
-7,812.8950
-3,475.5340
-16,038.1070
-15,974.9440
Net Non Operating Interest Income Expense
1,523.8980
219.4300
61.6390
137.4870
114.2570
Other Income Expense
-4.3170
5,421.5920
-2,389.1520
-8,639.0000
--
Pretax Income
-11,947.1790
-2,171.8730
-5,803.0470
-24,539.6200
-15,860.6870
Tax Provision
--
--
--
-443.8930
-1,675.3810
Net Income Common Stockholders
-11,947.1790
-2,171.8730
-5,803.0470
-24,095.7270
-16,135.6840
Diluted NI Available to Com Stockholders
-6,522.9280
-2,171.8730
-5,803.0470
-24,095.7270
-16,135.6840
Basic EPS
-2.17
-0.82
-11.20
-18.57
-22.50
Diluted EPS
-2.17
-0.82
-11.20
-18.57
-22.50
Basic Average Shares
7,463.9220
2,661.4160
518.1400
1,297.9060
717.7590
Diluted Average Shares
7,463.9220
2,661.4160
518.1400
1,297.9060
717.7590
Total Operating Income as Reported
-13,466.7600
-7,812.8950
-3,475.5340
-24,677.1070
-15,974.9440
Total Expenses
13,466.7600
7,812.8950
3,475.5340
16,038.1070
15,974.9440
Net Income from Continuing & Discontinued Operation
-11,947.1790
-2,171.8730
-5,803.0470
-24,095.7270
-14,185.3060
Normalized Income
-11,947.1790
-2,171.8730
-5,803.0470
-15,612.9964
-14,185.3060
Interest Income
1,523.8980
219.4300
62.2260
137.4870
114.2570
Interest Expense
--
--
0.5870
--
--
Net Interest Income
1,523.8980
219.4300
61.6390
137.4870
114.2570
EBIT
-7,825.7380
-2,171.8730
-5,802.4600
-16,038.1070
-15,974.9440
EBITDA
-7,825.7380
-2,171.8730
-5,802.4600
-15,944.6910
-15,871.7760
Reconciled Depreciation
--
--
--
93.4160
103.1680
Net Income from Continuing Operation Net Minority Interest
-11,947.1790
-2,171.8730
-5,803.0470
-24,095.7270
-14,185.3060
Total Unusual Items Excluding Goodwill
--
--
--
-8,639.0000
--
Total Unusual Items
--
--
--
-8,639.0000
--
Normalized EBITDA
-7,825.7380
-2,171.8730
-5,802.4600
-7,305.6910
-15,871.7760
Tax Rate for Calcs
--
--
--
0.0000
0.0001
Tax Effect of Unusual Items
--
--
--
-156.2694
--
12/31/2020 - 10/20/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GEM.F GeNeuro SA
0.1000
+4.60%
IBP0.F Bio-Path Holdings, Inc.
0.0000
-100.00%
CTRVP ContraVir Pharmaceuticals, Inc.
G51.F Genscript Biotech Corporation
1.2300
0.00%
ENM.DU CASI Pharmaceuticals Inc
1.4800
0.00%
L9S.DU Gyre Therapeutics Inc
9.20
-1.60%
L8S.F Grace Therapeutics, Inc.
0.0000
-100.00%
INCPF InnoCare Pharma Limited
3.2600
0.00%
GNIIF GNI Group Ltd.
19.88
-8.85%
GNRO.PA GeNeuro SA
0.1020
-10.53%